RxDoctor Payments Data

Neil Gordon, MD

Internal Medicine · Cedartown, GANPI 1376512301

Payments from drug & device makers

$1,659in general payments, 2019–2025

Across 101 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$647
  • Edwards Lifesciences$395
  • Pfizer$125
  • Amgen$115
  • Lilly USA, LLC$66
  • Johnson & Johnson$30
  • plus $281 from 13 others

What the payments were for

  • Travel & lodging$39524%
  • Food & beverage$1,26476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,659 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$97,612
Medicare patients
205
Services billed
9,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$94,725
OzempicSemaglutide71$82,984
JardianceEmpagliflozin51$63,449
XareltoRivaroxaban40$33,429
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen758$22,295
TrintellixVortioxetine Hydrobromide27$21,384
JanuviaSitagliptin Phosphate28$19,237
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,081
VraylarCariprazine Hcl13$18,059
Repatha SureclickEvolocumab18$17,532
TradjentaLinagliptin16$12,222
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$8,976
Breo ElliptaFluticasone/Vilanterol16$8,763
LantusInsulin Glargine,hum.Rec.Anlog20$7,078
Combivent RespimatIpratropium/Albuterol Sulfate13$6,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$94,72574 claims
Novo NordiskOzempic$20$82,98471 claims
Johnson & JohnsonXarelto$30$33,42940 claims
GSKTrelegy Ellipta, Breo Ellipta$26$26,84339 claims
AbbVieVraylar$647$18,05913 claims
Sanofi-aventis U.S. LLCLantus$28$7,07820 claims
Lilly USA, LLCHumulin N$66$3,43317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Cedartown

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →